ISSUES THAT MAY AFFECT ACCESS
TO COMPOUNDED MEDICATIONS
The Food and Drug Administration (FDA) Memorandum of Understanding (MOU)
The Food and Drug Administration (FDA) is using an obscure provision of federal law to try to deny patients access to compounded medications, including bioidentical hormone replacement therapy (BHRT). Here is how it works.
The Food & Drug Administration (FDA) has contracted with the National Academy of Science, Engineering and Medicine (NASEM) to determine whether women need the option of compounded bioidentical hormone replacement therapy (BHRT), or whether existing manufactured drugs made by the large drug companies can meet this need.